Arix Bioscience (ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high
risk-return profile of early-stage biotech investing. ARIX minimises risk through its expert investment team and with portfolio diversification. Strong interim results, which saw the NAV rise 24% to £251.0m, highlighted the enormous disconnect between this and its share price. ARIX has prioritised 11 companies in the portfolio on which to focus its resources and expertise. These have a number of important value inflection points – mostly clinical events – over the next 12-18 months.
If you'd like to be introduced to the team at Arix Bioscience, get in touch.Request a meeting